Transcriptomic signature of pulmonary hypertension secondary to valvular heart disease highlights BMPR2 as a key target: insights from the SIOVAC trial
Jorge Martínez-Solano, Jaime Bermejo-Fernández, Ana González‐Mansilla, Andres Gallardo-Jaramago et autres